Serum cardiac biomarkers, such as a new rise in Troponin I/T, B-type natriuretic peptide (BNP), or N-terminal B-type natriuretic peptide (NT-proBNP) have been well documented as indicators of cancer therapy-related cardiac dysfunction [19,21]. Here, NPPB is linked to cancer.